Hairy cell leukemia: update on molecular profiling and therapeutic advances, Blood Rev, vol.28, pp.197-203, 2014. ,
Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series, Blood, vol.123, pp.177-83, 2014. ,
Immunoconjugates and new molecular targets in hairy cell leukemia, Hematol Am Soc Hematol Educ Program, vol.2012, pp.660-666, 2012. ,
How I manage patients with hairy cell leukaemia, Br J Haematol, vol.177, pp.543-56, 2017. ,
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis, Br J Haematol, vol.145, pp.733-773, 2009. ,
Hairy cell leukemia: past, present and future, Best Pract Res Clin Haematol, vol.28, pp.269-72, 2015. ,
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients, Cancer, vol.116, pp.4788-92, 2010. ,
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia, Blood, vol.129, pp.553-60, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02194198
Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia, N Engl J Med, vol.373, pp.1733-1780, 2015. ,
Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia, Br J Haematol, vol.115, pp.609-620, 2001. ,
Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia, Haematologica, vol.86, pp.1046-50, 2001. ,
Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia, Blood, vol.102, pp.810-813, 2003. ,
Rituximab in relapsed or refractory hairy cell leukemia, Blood, vol.102, pp.3906-3917, 2003. ,
Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab. Leuk Lymphoma, vol.49, pp.1817-1837, 2008. ,
Eradication of minimal residual disease in hairy cell leukemia, Blood, vol.107, pp.4658-62, 2006. ,
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia, Blood, vol.118, pp.3818-3841, 2011. ,
Bendamustine and rituximab in relapsed and refractory hairy cell leukemia, Clin Cancer Res, vol.19, pp.6313-6334, 2013. ,
Efficacy and safety of the bruton tyrosine kinase inhibitor ibrutinib in patients with hairy cell leukemia: stage 1 results of a phase 2 study, Blood, vol.128, p.1215, 2016. ,
Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox, Clin Cancer Res, vol.17, pp.6398-405, 2011. ,
Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase I results and long-term follow-up, Blood, vol.131, issue.21, pp.2331-2335, 2018. ,
Moxetumomab pasudotox induces high rates of durable complete response and eradication of minimal residual disease in heavily pretreated patients with relapsed/refractory hairy cell leukemia: results of a pivotal international study (abstract), p.59 ,
, Annual Meeting of the American Society of Hematology, 2017.
,
Characteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysis, J Comp Eff Res, vol.6, pp.497-508, 2017. ,
Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping, Leuk Lymphoma, vol.52, issue.2, pp.65-73, 2011. ,
Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia, Arch Pathol Lab Med, vol.130, pp.374-381, 2006. ,
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patient with hairy cell leukemia, J Clin Oncol, vol.30, pp.1822-1830, 2012. ,
Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia, J Clin Oncol, vol.27, pp.2983-90, 2009. ,
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairycell leukemia, N Engl J Med, vol.345, pp.241-248, 2001. ,